Global Urea Cycle Disorder Market Size

Urea Cycle Disorder Market Analysis

The Urea Cycle Disorder Market is expected to grow at a significant CAGR of 3.4% during the study period (2022-2027).

In recent times, countries have faced a huge threat of COVID-19. According to the World Health Organization (WHO), coronavirus is an infectious disease, and most people infected with the COVID-19 virus will experience mild to moderate respiratory illness.

The emergence of the COVID-19 pandemic harmed the world economy and the healthcare system. The article 'Longitudinal Metabolomics Reveals Ornithine Cycle Dysregulation Correlates With Inflammation and Coagulation in COVID-19 Severe Patients,' published in December 2021, identified that the ornithine cycle dysregulation is significantly correlated with inflammation and coagulation in severe patients, which may be a potential mechanism of COVID-19 pathogenicity. Therefore, the COVID-19 medications hampered the urea cycle, leading to a deficiency of certain enzymes. Hence, there is an increasing demand for its therapeutics, contributing to market growth.

However, the production of these drugs was hampered due to the temporary lockdown in the manufacturing plants, shortage of skilled labor, and increasing cases of COVID-19 inside the manufacturing plants, which has led to outages, thus, impacting the market. Hence, the above factors indicate that COVID-19 significantly impacted the studied market.

The factors propelling the studied market growth are the rising prevalence of urea cycle disorders and the increasing number of pipeline products. Product launches, approvals, and strategic initiatives by key market players are expected to contribute to significant market growth.

Hyperammonemia is a metabolic condition characterized by raised ammonia levels, a nitrogen-containing compound. Consequently, urea cycle disorders lead to an accumulation of ammonia. Ammonia is extremely toxic, particularly to the central nervous system. As per the article published in Statpearls in November 2021, the prevalence of ornithine transcarbamylase deficiency-led urea cycle disorder is estimated to be 1in 140,000 people. It is the most common type of urea cycle disorder. Although it is a rare disease, its prevalence, if found to increase, thereby effective therapeutics are demanded, thus, driving the market.

Additionally, research and development studies highlighting the genetic characterization of urea cycle disorders will help market players align their product development, contributing to market growth. For instance, the study titled 'Clinical and Genetic Characterization and Biochemical Correlation at Presentation in 48 Patients Diagnosed with Urea Cycle Disorders at the Hospital Juan P Garrahan, Argentina,' published in September 2021, demonstrated that patients with early onset of the disease suffer the most severe forms and still have high morbimortality. At the same time, patients with late-onset are less severe and finally diagnosed due to one or more acute episodes.

Moreover, strategic initiatives such as partnerships, expansions, and acquisitions will also lead to significant market growth. For instance, in October 2021, Boehringer Ingelheim and Thoeris GmbH announced a collaboration and license agreement to investigate novel first-in-class therapies for patients with urea cycle disorders (UCDs). Such partnership will help players leverage their expertise and expand their product offerings, thus propelling the market.

Therefore, owing to the factors mentioned above, the studied market is expected to grow significantly during the study period. However, the high cost of therapeutics is expected to hinder the market growth during the forecast period.